newsfilter
← Latest News
GlobeNewswire·

Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements

Two patients exceed 14 months on treatment in Phase 2 trial of advanced ovarian cancerAllarity maintains a cash balance of $18.5 million, sufficient to advance and accelerate stenoparib's clinical development toward